AR and prostate cancer: Additionally, selective AR modulators or SARMs (e.g., enobosarm), investigational drugs first intended to be used as an alternative to testosterone therapies for male hypogonadism as well as related conditions such as muscle dystrophy, sarcopenia, or osteoporosis, are also currently being tested in clinical trials for both prostate cancer and TNBC [95,99,100].